Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$25.28 USD

25.28
1,876,172

-0.03 (-0.12%)

Updated Aug 26, 2024 04:00 PM ET

After-Market: $25.28 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth C Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 25% (188 out of 251)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Surmodics (SRDX) Q2 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research

Surmodics (SRDX) records higher revenues in both its core units in the fiscal second quarter.

CONMED (CNMD) Earnings and Revenue Surpass Estimates in Q1

by Zacks Equity Research

CONMED (CNMD) witnesses growth in revenues in both its segments during Q1.

LabCorp (LH) Q1 Earnings Surpass Estimates, View Raised

by Zacks Equity Research

LabCorp's (LH) raises 2021 guidance but projects significant sinking of COVID-related testing revenues.

Amedisys (AMED) Q1 Earnings Beat Estimates, 2021 View Up

by Zacks Equity Research

Amedisys' (AMED) first-quarter 2021 revenues improves year over year on solid growth in the Home Health and Hospice divisions.

OPKO Health (OPK) Q1 Earnings Match Estimates, Revenues Top

by Zacks Equity Research

OPKO Health's (OPK) first-quarter results benefit from strength in diagnostics.

Integra (IART) Q1 Earnings Beat Estimates, Gross Margin Down

by Zacks Equity Research

Integra's (IART) first-quarter revenues improved year over year on organic growth across Codman Specialty Surgical and Tissue Technologies segments.

Baxter (BAX) Q1 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Baxter's (BAX) first-quarter results reflect robust performance across five of its business units.

Chemed (CHE) Q1 Earnings Beat Estimates, Gross Margin Up

by Zacks Equity Research

Chemed's (CHE) first-quarter 2021 revenues increase year-over-year on solid growth across its Roto-Rooter arm.

Accuray (ARAY) Posts Breakeven Q3 Earnings, Beats on Revenues

by Zacks Equity Research

Accuray (ARAY) registers growth in Service and Product revenues during fiscal Q3.

Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Owens & Minor (OMI) witnesses rebound in demand for elective procedures through the months of Q1.

Boston Scientific (BSX) Q1 Earnings Beat, Organic Sales Up

by Zacks Equity Research

Boston Scientific (BSX) registers strong sequential improvement in overall financial performance in Q1.

Stryker (SYK) Earnings and Revenues Miss Estimates in Q1

by Zacks Equity Research

Stryker's (SYK) first-quarter earnings reflect strong performance across Orthopaedics and Neurotechnology and Spine segments.

InMode (INMD) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have continued to contribute to the company's Q1 top line.

Masimo (MASI) Earnings and Revenues Beat Estimates in Q1

by Zacks Equity Research

Masimo (MASI) continues to gain from its key Product segment, which makes a solid progress in Q1.

Ecolab (ECL) Q1 Earnings Miss, Revenues Surpass Estimates

by Zacks Equity Research

Although Ecolab's (ECL) first-quarter results reflect weakness in the Global Industrial and Institutional segments, its Global Healthcare and Life Sciences unit shows strength.

Quest Diagnostics (DGX) Q1 Earnings Miss, Base Recovery Strong

by Zacks Equity Research

The updated first-half 2021 outlook by Quest Diagnostics (DGX) looks impressive given its raised revenue and operating cash flow expectations.

Here's Why You Should Retain AmerisourceBergen (ABC) Stock

by Zacks Equity Research

AmerisourceBergen (ABC) continues to gain traction from robust pharmaceutical segment and new product launches.

Intuitive Surgical (ISRG) Q1 Earnings & Revenues Top Estimates

by Zacks Equity Research

Intuitive Surgical's (ISRG) first-quarter results reflect strong segmental performance.

Abbott (ABT) Q1 Earnings Miss, Diagnostic Test Sales Solid

by Zacks Equity Research

Abbott (ABT) reports strong Diagnostics sales for the first quarter driven by growing demand for its BinaxNOW, Panbio and ID NOW rapid testing platforms.

Here's Why You Should Retain Stryker (SYK) Stock Right Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako and broad product portfolio. However, pricing pressure raises a concern.

Veeva Systems (VEEV) Inks Deal to Advance Clinical Trials

by Zacks Equity Research

Veeva Systems (VEEV) collaborates with Parexel to accelerate clinical trials by combining the best of each company's experience.

Here's Why You Should Hold on to LabCorp (LH) Stock Now

by Zacks Equity Research

Investors are optimistic about LabCorp (LH) backed by its strong diagnostic arm growth and progress in Covance business.

Urmimala Biswas headshot

MedTech M&A Scaling New Heights in 2021 on Rising Investor Wealth

by Urmimala Biswas

While smaller tuck-in acquisitions dominated the M&A space throughout 2020, 2021 is seeing a number of colossal deals.

Medtronic (MDT) Boosts Diabetes Management via New Infusion Set

by Zacks Equity Research

Medtronic's (MDT) recently introduced Medtronic Extended infusion set with longer wearability enhances convenience and comfort, thus improving diabetes care.

Trina Mukherjee headshot

Dental Market Shows Strength Despite Pandemic: 3 Stocks to Watch

by Trina Mukherjee

Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.